Hyperinsulinism clinical trials

Explore recruiting hyperinsulinism clinical trials.

Recruiting hyperinsulinism studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hyperinsulinism trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients with Congenital Hyperinsulinism

Denmark, Spain, Greece, Bulgaria, France, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multiple Ascending Dose, Open-label, Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI) (ACHIEVE)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Single-Arm, Open-label, Pivotal Study to Evaluate the Efficacy and Safety of Ersodetug Compared to Baseline in Patients with Inadequately Controlled Hypoglycemia Due to Tumor-Associated Hyperinsulinism (Tumor HI)

France, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hyperinsulinism trials by city

Hyperinsulinism in Toronto Hyperinsulinism in Vancouver Hyperinsulinism in Montreal Hyperinsulinism in Calgary Hyperinsulinism in Edmonton Hyperinsulinism in Ottawa Hyperinsulinism in Winnipeg Hyperinsulinism in Quebec City Hyperinsulinism in Hamilton Hyperinsulinism in Kitchener Hyperinsulinism in London Hyperinsulinism in Halifax Hyperinsulinism in New York Hyperinsulinism in Los Angeles Hyperinsulinism in Chicago Hyperinsulinism in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease